激素替代疗法与乳腺癌风险

HT and breast cancer risk.

作者信息

Geller Michelle L, Chlebowski Rowan T

机构信息

Harbor-UCLA Research and Education Institute, Torrance, CA 90502, USA.

出版信息

Fertil Steril. 2003 Oct;80 Suppl 4:5-9; quiz 54-5. doi: 10.1016/j.fertnstert.2003.08.003.

DOI:10.1016/j.fertnstert.2003.08.003

PMID:14568281

Abstract

Two large recent studies indicate an increased risk of breast cancer with use of menopausal hormone therapy (HT), particularly combinations of estrogen and progestogen. These studies also go against previous theories of the types of breast cancer that would be associated with HT use. Emerging information regarding the influence of estrogen plus progestin on breast cancer risk adds further weight to the recommendation against use for chronic disease risk reduction and raises additional questions regarding risks of even short-term use for vasomotor symptoms associated with menopause.

摘要

最近两项大型研究表明，使用绝经激素疗法（HT），尤其是雌激素和孕激素联合使用，会增加患乳腺癌的风险。这些研究也与先前关于与使用HT相关的乳腺癌类型的理论相悖。关于雌激素加孕激素对乳腺癌风险影响的新信息，进一步支持了不建议使用该疗法来降低慢性病风险的建议，并引发了关于即使短期使用该疗法来缓解绝经相关血管舒缩症状的风险的更多问题。